GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forte Biosciences Inc (NAS:FBRX) » Definitions » Property, Plant and Equipment

Forte Biosciences (Forte Biosciences) Property, Plant and Equipment : $0.11 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Forte Biosciences Property, Plant and Equipment?

Forte Biosciences's quarterly net PPE increased from Sep. 2023 ($0.10 Mil) to Dec. 2023 ($0.11 Mil) but then declined from Dec. 2023 ($0.11 Mil) to Mar. 2024 ($0.11 Mil).

Forte Biosciences's annual net PPE stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.11 Mil).


Forte Biosciences Property, Plant and Equipment Historical Data

The historical data trend for Forte Biosciences's Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forte Biosciences Property, Plant and Equipment Chart

Forte Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Property, Plant and Equipment
0.10 - - 0.11

Forte Biosciences Quarterly Data
Jun19 Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.03 0.10 0.11 0.11

Forte Biosciences Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the companyFixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.


Forte Biosciences  (NAS:FBRX) Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Forte Biosciences Property, Plant and Equipment Related Terms

Thank you for viewing the detailed overview of Forte Biosciences's Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.


Forte Biosciences (Forte Biosciences) Business Description

Traded in Other Exchanges
Address
3060 Pegasus Park Drive, Building 6, Dallas, TX, USA, 75247
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease ("GvHD"), vitiligo and alopecia areata ("AA"). The company is developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric patients with atopic dermatitis. It plans to advance FB-401 into a randomized Phase 2 clinical trial.
Executives
Paul A. Wagner director, officer: See Remarks C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
Scott C. Brun director C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Hubert C Chen officer: See remarks C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Stephen K Doberstein director 129 ELSIE STREET, SAN FRANCISCO CA 94110
Barbara K Finck director C/O PROTINE DESIGN LAB, 3858 JACKSON ST, SAN FRANCISCO CA 94118
Antony A Riley officer: Chief Financial Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538
Thomas E Darcy director C/O SCIENCE APPLICATIONS INTL CORP, 10260 CAMPUS POINT DR., SAN DIEGO CA 92121
Donald Allen Williams director C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036
Patricia S Walker director 5540 EKWILL ST STE D, SANTA BARBARA CA 93111
Lawrence Eichenfield director C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Steven Kornfeld director C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Steven Michael Oliveira 10 percent owner 18 FIELDSTONE COURT, NEW CITY NY 10956
Fairooz Kabbinavar officer: SVP Clinical Development C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Mark G Foletta officer: EVP & Chief Financial Officer AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121

Forte Biosciences (Forte Biosciences) Headlines